Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials

syn53181385

Created By NF Service nf-osi-service

grantDOI: https://doi.org/10.48105/CTF.CTF-2023-10-003.pc.gr.175365
studyName: Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials
dataStatus: Data Pending
initiative: Clinical Research Award
studyLeads: Vanessa Merker
studyStatus: Active
diseaseFocus: Neurofibromatosis type 2
institutions: Massachusetts General Hospital
fundingAgency: CTF
manifestation: Quality of Life
studyFileviewId: syn53181393
syn53181386
syn53181387
syn53181393
syn53181388

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials page is loading…

Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials

syn53181385

Drop files to upload

Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials page is loading…